Special Issue "Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research 2014-2015"
Deadline for manuscript submissions: 31 December 2014
Dr. Jens H. Kuhn
NIH/NIAID Integrated Research Facility at Fort Detrick (IRF-Frederick), B-8200 Research Plaza, Fort Detrick, Frederick, MD 21702, USA
Phone: +1 301 631 7245
Fax: +1 301 631 7389
Interests: arenaviruses; biodefense; bioengagement; BSL-4; filoviruses; henipaviruses; Kyasanur Forest disease virus; nairoviruses; phleboviruses; Omsk hemorrhagic fever virus; simian hemorrhagic fever virus
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed Open Access monthly journal published by MDPI.
Article: ABSL-4 Aerobiology Biosafety and Technology at the NIH/NIAID Integrated Research Facility at Fort Detrick
Viruses 2014, 6(1), 137-150; doi:10.3390/v6010137
Received: 25 September 2013; in revised form: 18 December 2013 / Accepted: 20 December 2013 / Published: 7 January 2014| Cited by 1 | PDF Full-text (7919 KB) | HTML Full-text | XML Full-text
Article: Clinical Documentation and Data Transfer from Ebola and Marburg Virus Disease Wards in Outbreak Settings: Health Care Workers’ Experiences and Preferences
Viruses 2014, 6(2), 927-937; doi:10.3390/v6020927
Received: 13 December 2013; in revised form: 8 February 2014 / Accepted: 11 February 2014 / Published: 19 February 2014| PDF Full-text (510 KB) | HTML Full-text | XML Full-text | Supplementary Files
Viruses 2014, 6(4), 1654-1671; doi:10.3390/v6041654
Received: 25 November 2013; in revised form: 27 March 2014 / Accepted: 30 March 2014 / Published: 9 April 2014| PDF Full-text (1763 KB) | HTML Full-text | XML Full-text
Meeting Report: Challenges, Progress, and Opportunities: Proceedings of the Filovirus Medical Countermeasures Workshop
Viruses 2014, 6(7), 2673-2697; doi:10.3390/v6072673
Received: 22 April 2014; in revised form: 1 July 2014 / Accepted: 1 July 2014 / Published: 9 July 2014| PDF Full-text (582 KB) | HTML Full-text | XML Full-text | Supplementary Files
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Validation of a Standardized Filovirus Plaque Assay for Titration of Marburg and Ebola Viruses
Authors: Amy C. Shurtleff1, Holly Bloomfield2, Michelle Richards3, Lucinda Leaman3, Shannon M. Mort4, Steve Orr4, Wendy Giles4, Donna Hering5, Han Seung5, Kelly Masonic5, Susan Newcomb4 and Sina Bavari1
1 Molecular and Translational Sciences Division
2 Aerobiology Division
3 Virology Division
4 Nonclinical Development Division
5 Quality Assurance and Regulatory Compliance Office
United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD, 21702
Abstract: A plaque assay for method for quantitating filoviruses in virus stocks, prepared viral challenge inocula and serum and plasma samples from research animals has recently been fully characterized and standardized for use across multiple institutions performing BSL-4 studies. After standardization studies were completed, GLP plaque assay method validation efforts to demonstrate that the plaque assay is suitable for reliable and reproducible measurement of Marburg Virus Angola variant and Ebola virus Kikwit variant commenced at USAMRIID. Validation parameters tested included accuracy, precision, linearity, stability of the virus stocks and system suitability. Robustness studies were completed to evaluate the effect of cell passage number, stability of virus samples, time of cell seeding, appropriate day to stain and count plaques, lower limit of quantitation (LLOQ) and detection (LOD), and change in inoculum volume and cell culture vessel. The virus titer values of qualified quality control (QC) samples, alongside a negative control (NC) and a virus positive control (PC) of known titer, were repeatedly analyzed to determine the assay’s performance. The MARV assay was confirmed to be accurate to ± 0.5 log10 PFU/mL, based on routine passing of this acceptance criterion to define accuracy. In addition, repeatability precision, intermediate precision, and reproducibility precision, when the assay was performed by 2 analysts, were sufficiently precise to return viral titers with a %CV measure of ≤ 30%, which is acceptable variation for such a cell-based bioassay. Intraclass correlation statistical techniques for evaluation of the assay’s precision when the same plaques were quantitated by 2 analysts returned calculations of at least 0.9234 with lower 95% confidence limits (CI) ≥ 0.8914 and upper 95% CI ≥ 0.9382 for 4 assay runs. The assay confirmed linearity for QC samples prepared as tenfold dilutions, where R2 = 0.83. The assay was shown to be accurate and specific when run on NHP serum and plasma samples diluted in plaque assay medium, with negligible matrix effects. MARV and EBOV validation data will be presented. Overall, the results demonstrated that the assay was accurate, precise and robust for use to titrate filoviruses in samples associated with the performance of GLP animal model studies.
Last update: 19 August 2014